Progeria

Disease Description (Causes and Pathophysiology, Main Symptoms)

• Definition/Cause: Hutchinson-Gilford progeria syndrome (progeria) is a rare genetic disorder caused in most cases by LMNA gene mutations (LMNA on chromosome 1q; commonly splicing abnormalities such as c.1824C>T that result in production of the progerin protein). Although its inheritance pattern is autosomal dominant, it actually arises in most cases from a de novo (new) mutation that is not inherited from the parents.
• Pathophysiology: Abnormal lamin A (progerin) proteins damage the structure of the nuclear membrane and nuclear function, causing cellular senescence, instability of the cytoskeleton and nucleus, and dysfunction of adipocytes, vascular endothelial cells, and smooth muscle cells. This leads to a pattern of premature systemic aging and, particularly, accelerated atherosclerosis.
• Main symptoms (age at onset/course):
  • Growth arrest (short stature and low body weight) and developmental delay beginning around 9–24 months after normal birth
  • A small face relative to the head, a small jaw (micrognathia), and dental abnormalities
  • Progressive frontal and generalized hair loss beginning around 2 years of age (loss of hair, eyebrows, and eyelashes), with hair becoming thin and lighter in color
  • Subcutaneous fat atrophy, thinning and wrinkling of the skin, and abnormal bone development (osteogenesis imperfecta, bone resorption)
  • Limited joint range of motion and stiffness, with reduced muscle mass
  • Cardiovascular complications due to early progressive atherosclerosis (myocardial infarction, angina pectoris, and heart failure), with increased risk of stroke
  • High-pitched voice, delayed or incomplete sexual maturation, and possible hearing loss

Treatment

• Definitive treatment: There is no cure. Gene and molecular therapy research (e.g., RNA-targeted therapy and gene editing) is ongoing, but these have not been established as standard treatments.
• Drug treatment (current standard recommendations/clinical application):
  • Lonafarnib (a farnesyltransferase inhibitor, brand name Zokinvy): This drug has shown reduced mortality and improvement in some cardiovascular indicators in Hutchinson-Gilford Progeria Syndrome, and there are approved and clinical-use cases (indications and use should be determined by a specialist).
  • Low-dose aspirin: Recommended at many centers to prevent thrombotic and ischemic events (individual risk–benefit assessment is required).
  • Cardiovascular risk management: Standard treatments for cardiovascular disease, such as statins, antihypertensive drugs, and antiplatelet drugs, may be used as needed.
• Non-drug/supportive treatment:
  • Regular cardiac (echocardiography and electrocardiography) and vascular (blood pressure and blood lipid) monitoring and early treatment
  • Growth and nutritional management: Collaboration with a dietitian to optimize intake and nutritional status
  • Physical and occupational therapy: Maintaining joint range of motion and supporting strength and function
  • Dental treatment and orthodontics: Management of chewing and dental problems
  • Orthopedic treatment: Individualized surgical approaches may be considered in cases of severe skeletal abnormalities or joint problems
  • A multidisciplinary approach, including hearing, ophthalmologic, and skin care
• Precautions and risk of complications:
  • The main causes of death are cardiovascular complications (myocardial infarction and stroke). Regular cardiovascular monitoring and active management of risk factors are necessary.
  • Because cardiovascular risk is high during surgery and anesthesia, anesthesia risk assessment and cardiac evaluation should be performed beforehand.
  • Some medications (e.g., lonafarnib) have side effects (such as gastrointestinal symptoms and weight loss) and drug interactions, requiring specialist management.
  • Prevention and early treatment of complications such as infections, malnutrition, fractures, and joint problems are important.

Checklist Before an Outpatient Visit (Including Items to Bring and Sample Questions)

• Items/documents to bring:
  • A list of all currently used medications and supplements with dosages (including copies of prescriptions)
  • Previous genetic test results (the original report if an LMNA mutation result is available)
  • Recent test results (blood tests, lipid tests, electrocardiogram, echocardiography reports, and imaging studies)
  • Growth charts (height and weight tracking data) and photographs showing symptom progression (age-by-age comparisons can be useful if available)
  • Vaccination records, allergy information, and records of previous surgeries and hospitalizations
  • Family history (cardiovascular disease, genetic disorders, etc.)
• Examples of questions to organize before the visit (it is useful for patients/guardians to write these down in advance):
  • When symptoms began and how quickly they have changed (When did they start, and which area worsened first?)
  • Whether there have been recent changes in weight or food intake, and changes in fatigue or exercise capacity
  • Whether cardiovascular or neurological symptoms such as chest pain, shortness of breath, fainting, headache, or visual disturbances are present

Examples of General Questions to Ask the Doctor

• "What is the expected course (prognosis) of this disease? What are the main factors that affect survival?"
• "What are the currently recommended standard treatments and management schedule (such as testing intervals)?"
• "What are the main side effects of this medication (or treatment), and what monitoring is needed?"
• "What should we be careful about in daily life (exercise, nutrition, vaccinations, precautions before surgery, etc.)?"
• "How will collaborative care with other specialties (cardiology, orthopedics, dentistry, nutrition, etc.) be arranged?"

Examples of Disease-Specific Questions

• "Is lonafarnib (or a related clinically used medication) appropriate for me (or the patient)? Please explain the expected benefits and possible side effects."
• "What tests (such as echocardiography, CT angiography, and blood lipid testing) should be performed, and at what intervals, to detect cardiovascular complications early?"
• Additional: "Is genetic counseling needed regarding family planning? Please explain the possibility of passing this condition on to future children."

(Note: The information above is general information about medical care, testing, and treatment. Its application may vary depending on the individual patient's condition, so please discuss it in detail with your medical team.)